Assessment of Efficacy of first-line EGFR tyrosine kinase inhibitor other than Osimertinib in patients with EGFR-mutant Non-small cell lung cancer in terms of longer progression free survival
Latest Information Update: 16 Oct 2020
At a glance
- Drugs Afatinib (Primary) ; Erlotinib (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 16 Oct 2020 New trial record
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress